Antares Pharma Shares Outstanding 2006-2019 | ATRS

Antares Pharma shares outstanding from 2006 to 2019. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Antares Pharma Annual Shares Outstanding
(Millions of Shares)
2019 163
2018 157
2017 156
2016 155
2015 147
2014 131
2013 127
2012 110
2011 97
2010 83
2009 73
2008 67
2007 60
2006 52
2005 41
Antares Pharma Quarterly Shares Outstanding
(Millions of Shares)
2019-12-31 163
2019-09-30 169
2019-06-30 163
2019-03-31 160
2018-12-31 157
2018-09-30 157
2018-06-30 157
2018-03-31 157
2017-12-31 156
2017-09-30 156
2017-06-30 156
2017-03-31 155
2016-12-31 155
2016-09-30 155
2016-06-30 155
2016-03-31 155
2015-12-31 147
2015-09-30 155
2015-06-30 145
2015-03-31 132
2014-12-31 131
2014-09-30 131
2014-06-30 130
2014-03-31 130
2013-12-31 127
2013-09-30 127
2013-06-30 126
2013-03-31 126
2012-12-31 110
2012-09-30 109
2012-06-30 105
2012-03-31 104
2011-12-31 97
2011-09-30 103
2011-06-30 95
2011-03-31 86
2010-12-31 83
2010-09-30 84
2010-06-30 83
2010-03-31 82
2009-12-31 73
2009-09-30 76
2009-06-30 68
2009-03-31 68
2008-12-31 67
2008-09-30 68
2008-06-30 67
2008-03-31 66
2007-12-31 60
2007-09-30 65
2007-06-30 55
2007-03-31 53
2006-12-31 52
2006-09-30 53
2006-06-30 53
2006-03-31 47
2005-12-31 41
2005-09-30 42
2005-06-30 41
2005-03-31 40
Sector Industry Market Cap Revenue
Medical Medical & Dental Supplies $0.391B $0.124B
Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients. The Company currently distributes its needle-free injector systems for the delivery of insulin and growth hormone in over 20 countries and an estradiol transdermal patch for hormone replacement therapy.
Stock Name Country Market Cap PE Ratio
Becton Dickinson (BDX) United States $62.307B 19.76
McKesson (MCK) United States $23.932B 9.39
AmerisourceBergen (ABC) United States $18.221B 12.22
Cooper (COO) United States $14.702B 22.67
Cardinal Health (CAH) United States $13.988B 8.73
Align Technology (ALGN) United States $13.699B 35.07
Laboratory Of America Holdings (LH) United States $12.298B 11.18
Straumann Holding AG (SAUHF) Switzerland $11.784B 0.00
West Pharmaceutical Services (WST) United States $11.243B 46.99
DENTSPLY SIRONA (XRAY) United States $8.598B 15.85
Henry Schein (HSIC) United States $7.244B 14.39
SmileDirectClub (SDC) United States $1.795B 0.00
Merit Medical Systems (MMSI) United States $1.726B 21.26
CONMED (CNMD) United States $1.632B 21.61
Patterson (PDCO) United States $1.465B 10.19
STAAR Surgical (STAA) United States $1.451B 67.21
Atrion (ATRI) United States $1.206B 32.94
Invacare (IVC) United States $0.252B 0.00
Lifevantage (LFVN) United States $0.147B 12.41
Pro-Dex (PDEX) United States $0.063B 16.88
Milestone Scientific (MLSS) United States $0.061B 0.00
Retractable Technologies (RVP) United States $0.051B 19.50
Endologix (ELGX) United States $0.013B 0.00
Biolase (BIOL) United States $0.012B 0.00